Northern Trust Corp Raises Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Northern Trust Corp boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 916,384 shares of the medical equipment provider's stock after purchasing an additional 96,275 shares during the period. Northern Trust Corp owned approximately 1.32% of Lantheus worth $81,980,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Empirical Asset Management LLC purchased a new position in Lantheus during the 4th quarter valued at about $323,000. Focus Financial Network Inc. bought a new position in Lantheus during the 4th quarter valued at approximately $292,000. Harbor Capital Advisors Inc. lifted its holdings in Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock worth $13,006,000 after buying an additional 16,466 shares during the period. Finally, World Investment Advisors LLC bought a new stake in shares of Lantheus in the 3rd quarter worth approximately $60,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lantheus has an average rating of "Buy" and an average price target of $132.67.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,109 shares of company stock valued at $6,016,046. Insiders own 2.00% of the company's stock.

Lantheus Stock Up 1.8 %

Shares of LNTH stock traded up $1.42 during trading hours on Friday, hitting $81.86. 1,561,064 shares of the company's stock traded hands, compared to its average volume of 966,297. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 13.62 and a beta of 0.23. The stock's fifty day simple moving average is $99.90 and its two-hundred day simple moving average is $94.57. Lantheus Holdings, Inc. has a 12-month low of $74.34 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company's revenue was up .8% compared to the same quarter last year. During the same period last year, the firm posted $1.69 earnings per share. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.